Actelion ‘Make or Break’ Drug

Actelion ‘Make or Break’ Drug

Actelion Pharmaceuticals Ltd/copyright 2011 via Bloomberg

Actelion is banking on macitentan to replace sales of its top-selling lung drug Tracleer, which accounted for 90 percent of product revenue in 2010 and starts to lose patent protection in 2015.